COMMUNIQUÉS West-GlobeNewswire

Avicanna Announces Change in CFO
13/09/2025
TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/09/2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/09/2025
DURHAM, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“ [...]
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
12/09/2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a [...]
4DMT Announces New Employment Inducement Grants
12/09/2025
EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
12/09/2025
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing [...]
Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis
12/09/2025
Expanded indication provides patients with knee osteoarthritis the benefits of Embosphere’s consistent, predictable, and effective clinical results. SOUTH JORDAN, Utah, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Merit Medical [...]
Voting Rights and Shares Capital of the Company
12/09/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 12, 2025 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
12/09/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 12 sept. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Sanofi: Information concerning the total number of voting rights and shares - August 2025
12/09/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2025
12/09/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
12/09/2025
AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing transformative oncology and [...]
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
12/09/2025
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “ [...]
Virbac: 2025 Half-year results
12/09/2025
Solid revenue growth in the first half of 2025 of +5.6% at constant exchange rates and scope Adjusted recurring operating income² of 18.3% as a ratio to revenue, in line with our expectations Down compared to 2024 due [...]
VIRBAC: résultats semestriels 2025
12/09/2025
Une solide croissance du chiffre d'affaires du premier semestre 2025 de +5,6% à taux de change et périmètre constants Résultat opérationnel courant ajusté 2 de 18,3% en ratio du chiffre d’affaires en ligne avec nos [...]
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
12/09/2025
The Group released and filed its 2025 half-year financial report with the French “Autorité des marchés financiers”. The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “ [...]
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2025
12/09/2025
Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier semestriel au 30 juin 2025. Le rapport financier semestriel peut également être consulté [...]
Virbac : Rapport financier semestriel 2025
12/09/2025
Ci-joint le rapport financier semestriel 2025 de Virbac Pièce jointe Rapport financier semestriel_2025
Virbac : Half-yearly financial report 2025
12/09/2025
Please find attached 2025 Half-yearly financial report of Virbac Attachment Half-Yearly Financial Report_2025

Pages